Aureomycin

Quick links to important sections

Aureomycin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aureomycin

Quick Facts

Property Description
Active ingredient Chlortetracycline (often as hydrochloride salt)
Form Capsules, tablets, ointment, ophthalmic ointment
Pharmacological class Tetracycline-class antibiotic
Common use Fighting bacterial infections
Origin Naturally derived (Streptomyces aureofaciens)

What is Aureomycin and Its Chemical Identity?

Aureomycin is the trade name for a medicine containing the active ingredient Chlortetracycline, which is chemically defined as a tetracycline derivative. Chlortetracycline is a naturally derived compound, originally isolated from the bacterium Streptomyces aureofaciens. Chlortetracycline is a broad-spectrum antibiotic that was introduced in 1948, establishing it as the first tetracycline antibiotic. This pioneering status is clinically recognized by infectious disease experts for setting the foundation for the entire class of related antibiotics.

This single-active-ingredient substance is frequently supplied as Chlortetracycline hydrochloride for stability. It is prepared in various high-level dosage form(s), including capsules and tablets for oral intake, and both ointment and ophthalmic ointment for topical administration. The availability of multiple forms allows for targeted treatment, such as the use of the ophthalmic ointment for superficial eye infections, representing a unique formulation approach.


Chlortetracycline’s Pharmacological Class and Purpose

Chlortetracycline is categorized as an antibiotic and belongs specifically to the tetracycline-class antibiotic group. The drug's central general purpose is to fight and resolve bacterial infections. As a broad-spectrum antibiotic, it is commonly used in scenarios where a wide variety of bacterial pathogens might be involved.

It achieves this by functioning as a bacteriostatic agent, meaning its primary action is not to destroy bacteria outright but rather to stop their ability to grow, spread, and reproduce. Pharmacological studies confirm that this specific mechanism, involving protein synthesis inhibition, effectively limits the proliferation of bacteria. This distinction in function—stopping growth versus outright killing—is a key characteristic of the tetracycline class, distinguishing it from bactericidal antibiotics.

What side effects are possible with Aureomycin?

Possible side effects and safety information

The official safety profile for Chlortetracycline (Aureomycin) is structured by government regulatory agencies (such as the FDA and EMA) around defined adverse reaction groupings and established class constraints. This structure informs the understanding of the medicine's documented risks, which vary based on formulation.


Adverse Reaction Scope

The most common adverse reactions reported for the topical/ophthalmic formulations are typically localized. These fall under Eye Disorders and Skin and Subcutaneous Tissue Disorders, including transient stinging, minor irritation, redness (erythema), and local sensitivity reactions at the application site. Hypersensitivity reactions are also documented.

Classification Examples of Reactions
Local Reactions Transient stinging, irritation, redness, local swelling, pruritus (itching)
Systemic Class Risks Photosensitivity, Superinfection

Serious Class Effects and Population Constraints

As a tetracycline-class drug, Chlortetracycline carries official warnings for potentially serious conditions and population-specific risks mandated for disclosure, even when the product is used topically or veterinarily.

Regulatory documents state that use of tetracyclines during the last half of pregnancy, infancy, and childhood (up to 8 years of age) may cause permanent discoloration of the teeth (yellow-gray-brown) and inhibition of bone growth. Furthermore, the class is associated with severe reactions such as Idiopathic Intracranial Hypertension (Pseudotumor Cerebri) and severe colitis (Clostridioides difficile-Associated Diarrhea).

Exposure-Related Patterns include a documented risk of photosensitivity, which is an exaggerated sunburn reaction requiring caution regarding sunlight exposure. Prolonged use is noted to carry the risk of superinfection from the overgrowth of non-susceptible organisms, including fungi.

The medicine is contraindicated in cases of known hypersensitivity to the active substance, to other tetracyclines, or to any component of the specific formulation.

Overdose and Emergency Response

Aureomycin Overdose and When to Seek Help

Regulatory information documents the potential for systemic toxicity associated with high exposure to the tetracycline drug class, to which Aureomycin (Chlortetracycline) belongs. Overdose manifestations may include general symptoms such as weakness, fever, fatigue, nausea, abdominal pain, and mild jaundice. Laboratory findings may show elevated levels of serum aminotransferase and alkaline phosphatase.

High-level systemic toxicity is classified as life-threatening and may lead to severe hepatic dysfunction, acute fatty liver, acute liver failure, renal dysfunction, and subsequent multiorgan failure. The official profile notes a specific population consideration: the risk of acute fatty liver syndrome is elevated in pregnant women, particularly during the last trimester or early postpartum period.

In the event of accidental exposure, especially if the product is swallowed, the regulatory labeling mandates immediate action. Individuals must seek medical help or contact a Poison Control Center right away. There is no specific antidote for tetracycline toxicity, which is also noted as not dialyzable. Management relies on the immediate discontinuation of the product and rigorous supportive measures, with severe cases requiring intensive care and monitoring of multiorgan function.

Therapeutic Uses of Aureomycin

The primary therapeutic use of Aureomycin is as a tetracycline-class antibiotic, with its active ingredient being chlortetracycline hydrochloride. It is not currently approved for systemic human use in major jurisdictions but is commonly used in livestock and poultry management. Its main indications involve use in situations involving certain distressing symptoms linked to bacterial causes. These uses are applied across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort related to symptoms related to inflammatory or irritative states and symptoms that create noticeable physiological strain.

Specific uses for which the product may assist include addressing symptom clusters such as those associated with bacterial enteritis (scours), bacterial pneumonia (shipping fever complex), anaplasmosis in cattle, and infectious synovitis in poultry. Aureomycin generally supports patients during episodes of heightened discomfort and may assist with maintaining functional stability. This generally may help ease the overall symptom burden in conditions characterized by periods of heightened symptoms in the animal species for which it is labeled.

“The product supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: May assist with Symptoms related to physical discomfort

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Aureomycin?

Eligibility for Aureomycin (Chlortetracycline) is strictly defined by regulatory documents, focusing on developmental stage, allergies, and organ function. This drug is part of the tetracycline class and its use is governed by official safety constraints.

Contraindications and Restrictions

Population/Condition Eligibility Status (Regulatory)
Children under 8 years Prohibited/Contraindicated (Risk of permanent tooth discoloration and enamel hypoplasia)
Pregnancy Prohibited (During second and third trimesters)
Hypersensitivity to Tetracyclines Contraindicated (Known allergy to the drug class)
Severe Hepatic Impairment Contraindicated

Use Requiring Caution

Individuals with pre-existing renal (kidney) or hepatic (liver) impairment require careful assessment. The official labeling indicates that use in these populations may be restricted or conditional, often requiring dose adjustments to prevent drug accumulation and potential toxicity. Aureomycin is generally approved for use in adults and adolescents over 8 years of age who do not present any of the absolute contraindications listed above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Aureomycin (chlortetracycline) establishes specific interaction-related constraints primarily based on two key mechanisms: the formation of non-absorbable complexes and alterations in therapeutic effects. This section summarizes the clinically significant interactions identified in authoritative government sources.


Documented Interaction Categories

Interacting Product Category Key Practical Implication
Metal Cation-Containing Products (e.g., Antacids, Iron, Calcium supplements, Bismuth) Reduced absorption of Aureomycin, requiring a mandatory separation of administration time to maintain adequate drug levels.
Oral Anticoagulants (e.g., Warfarin, Acenocoumarol) Potential increased anticoagulant effect due to the suppression of intestinal flora, requiring close monitoring of coagulation tests (e.g., INR).
Penicillins Potential antagonism of the bactericidal effect, as bacteriostatic drugs may interfere with the action of bactericidal antibiotics.
Specific Retinoids (e.g., Acitretin, Bexarotene) Increased risk of developing pseudotumor cerebri, leading to recommendations for avoidance or contraindication.

These documented interactions dictate that co-administration with metal-containing preparations must be carefully spaced. Furthermore, a dose adjustment of oral anticoagulants may be necessary, and specific combinations, particularly with retinoids, are restricted due to the heightened risk of serious adverse effects.

Mechanism of Action

Molecular Blockade of Bacterial Protein Synthesis

Aureomycin (chlortetracycline) acts by directly and reversibly binding to the bacterial 30S ribosomal subunit, specifically obstructing the aminoacyl-tRNA acceptor (A) site. This action prevents the incorporation of new amino acids, which halts the subsequent synthesis of structural and enzymatic proteins.


Translational Pathway Inhibition and Bacteriostasis

The direct inhibition of the translational elongation phase defines the drug's core mechanistic cascade, where molecular interference leads to the physiological outcome of suppressed growth. The consequence of this mechanism is a bacteriostatic effect, meaning the organism's ability to proliferate is arrested.


Resistance Pathways and Mechanistic Limitations

The drug's mechanism is constrained when bacteria engage in counter-measures, such as activating efflux pump proteins that actively expel the molecule or producing ribosomal protection proteins that prevent effective binding. These acquired resistance mechanisms directly diminish the drug's concentration at the target site, leading to an ineffective drug concentration at the target site.

Dosage and Administration Information

Administration scope

Route of administration: Oral, primarily delivered via medicated animal feed, top-dress on feed, or in drinking water, as authorized by a veterinarian.

Dosing schedule: The dose is highly variable, depending on the animal species, body weight, and specific condition being addressed. The dose is typically expressed in milligrams of chlortetracycline per pound of body weight per day or grams per ton of complete feed (e.g., 10 mg/lb body weight/day, or 70 mg/head/day). Treatment is administered continuously for a defined, short period, such as for not more than 5 days or continuously for 7 to 14 days.

Timing in relation to meals (if applicable): When administered as a top-dress, the medicated supplement must be spread uniformly on top of the ration to ensure all animals can consume the required dose. Solutions for calves must not be administered in milk or milk replacers.

Preparation requirements (if applicable): Aureomycin Type A Medicated Article requires specific dilution with feed ingredients to create a premix, which is then thoroughly mixed into the final Type C medicated feed. Soluble powder solutions for water administration must be prepared fresh daily.

Age-group administration rules: Use is not approved for female dairy cattle 20 months of age or older (including dry cows). Specific dosages apply to distinct age and weight classes, such as calves, growing cattle, and beef cattle over 700 lbs.

Special procedural conditions: The use of medicated feed or water containing Aureomycin is subject to a Veterinary Feed Directive (VFD) or Prescription (Rx) issued by a licensed veterinarian. This is mandatory, and the product must be used strictly as directed on the label and VFD order, with extra-label use strictly prohibited.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aureomycin

The research exploring the use of Aureomycin (Chlortetracycline) covers different formulations, including its original role as a pioneering antibiotic and its modern topical and veterinary uses. Available evidence includes older controlled trials and more recent effectiveness studies, each focusing on specific measures of change within defined populations. The findings provide context but do not offer personal predictions for individual responses.


Evidence for Topical Use in Chlamydial Ocular Infection

Research has studied Aureomycin in its ophthalmic ointment form in contexts involving bacterial infections of the eye, specifically those caused by the Chlamydia trachomatis organism. Studies conducted during periods of increased symptom activity have included randomized controlled trials (RCTs). These studies examined outcomes related to physical discomfort and sought to measure patterns related to microbiological clearance. Evidence quality varies, as much of the data is derived from older trials utilizing relatively small sample sizes (N approx 85).


Evidence for Topical Use in Severe Peri-implantitis

The active ingredient, Chlortetracycline, was evaluated as a local, adjunctive therapy in the context of severe peri-implantitis, a condition marked by functional limitations around dental implants. Studies explored its use alongside mechanical cleaning procedures in small-scale RCTs of adults. Research examined clinical parameters such as Probing Depth (PD) and outcomes linked to inflammatory or irritative states. Sample sizes were modest (N approx 32), limiting generalizability, and systematic reviews have noted high heterogeneity across measured study parameters.


Evidence from Field Trials for Veterinary Indications

Chlortetracycline was evaluated in regulatory field trials and effectiveness studies for use in various animal species, including livestock and poultry, for conditions like bacterial enteritis and pneumonia. The evidence describes patterns related to outcomes reflecting daily functioning (e.g., maintenance of weight) and studies monitored changes in disease-related symptoms. Evidence for these labeled uses is documented in regulatory fact sheets based on historical field effectiveness data.


Research Gaps and Areas of Uncertainty

Research exploring the effects has largely focused on short-term or intermediate-term outcomes. Long-term effects are not fully established, and follow-up durations were limited, providing little insight into the durability of observed changes. Evidence quality varies across studies, and comparative evidence against newer treatments is often lacking in the publicly available literature. The high variability in antibiotic resistance prevalence represents a significant ongoing area of research.

Frequently Asked Questions (FAQ)

Common questions about Aureomycin (FAQ)


Q: Is Aureomycin the same type of medicine as penicillin?

A: Aureomycin (chlortetracycline) belongs to the tetracycline class of antibiotics, which work by being bacteriostatic—meaning they stop bacterial growth. Penicillins belong to a different drug class and are typically bactericidal, meaning they kill bacteria. Official documents note that because of this difference in action, the two types of antibiotics may result in antagonism (opposing effects) if used concurrently.


Q: What conditions is Aureomycin most commonly used for?

A: Official regulatory documents categorize Aureomycin as a broad-spectrum antibiotic used in the management of a variety of bacterial infections. Regulatory-approved uses and research have specifically examined its application in formulations for ophthalmic (eye) infections and certain veterinary applications.


Q: Can Aureomycin be used for a skin infection?

A: Yes, chlortetracycline is available in an ointment formulation intended for topical antimicrobial use. According to regulatory labeling, it is explicitly marked as 'For external use only,' and labeling indicates that it is intended for application over small, affected areas of the skin.


Q: Are there common household products that interact with Aureomycin?

A: Yes, official documentation establishes a specific constraint regarding Metal Cation-Containing Products, which includes common items like antacids and certain iron or calcium supplements. Taking these products too closely to the medication can interfere with absorption, potentially resulting in reduced drug levels in the body.


Q: Does Aureomycin interact with common vitamins or supplements?

A: Official documentation notes an interaction constraint with supplements containing high levels of iron and calcium. The official information indicates separation is required to avoid interference with the drug's absorption.


Q: Is it common to feel tired while taking Aureomycin?

A: The tetracycline class of medicines is known to be associated with reports of central nervous system effects. These effects may include symptoms such as fatigue or tiredness. These symptoms are often reported to resolve after the course of medicine is completed.


Q: Can Aureomycin cause stomach upset or nausea?

A: As with many medicines in the tetracycline class, gastrointestinal disturbances, such as stomach upset or nausea, are among the most common adverse effects reported in medical literature.


Q: Does Aureomycin affect birth control pills?

A: Regulatory warnings for the tetracycline class indicate that using this type of antibiotic concurrently with oral contraceptives may reduce the effectiveness of the birth control pill.


Q: Why do doctors prescribe Aureomycin for eye infections?

A: Aureomycin is formulated as an ophthalmic ointment and is a broad-spectrum antibiotic with a known activity spectrum against the types of bacteria that cause superficial eye infections, such as Chlamydia trachomatis, as documented in research.


Q: Do I need to avoid certain foods when taking Aureomycin?

A: Official documentation advises against concurrent administration with foods or liquids containing high levels of calcium or other metal cations. This specifically includes milk or milk replacers, as this can significantly interfere with the medicine's absorption.


Q: Is feeling dizzy a possible side effect of Aureomycin?

A: Regulatory warnings for the tetracycline class acknowledge that central nervous system side effects have been reported. These effects can include dizziness, light-headedness, or vertigo.


Q: Is Aureomycin effective against viral infections?

A: No. Official documents define Aureomycin as an antibiotic; its mechanism of action targets only bacteria, and is used to manage bacterial infections. Antibiotics are not effective against illnesses caused by viruses.


Q: What are the signs of a serious allergic reaction to Aureomycin?

A: A severe allergic reaction (hypersensitivity) to the tetracycline class can manifest as severe skin rash or hives, swelling of the face, lips, or tongue, and difficulty breathing or swallowing. Dizziness or fainting can also occur. These symptoms may signify a severe reaction.


Q: Is there a generic version of Aureomycin available?

A: Aureomycin is the trade name for the medicine. The active ingredient, which is the non-branded or generic equivalent, is Chlortetracycline.


Q: Why is it important to finish the full course of Aureomycin?

A: Finishing the full course supports maintaining effective drug concentrations. This is important to prevent bacteria from surviving and developing resistance mechanisms, such as activating efflux pump proteins that expel the medication, as detailed in the drug’s official mechanism descriptions.


Q: Does Aureomycin cause yeast infections?

A: Official safety documents indicate that prolonged use of the medicine carries a risk of superinfection (a second infection). This happens due to the overgrowth of non-susceptible organisms, which includes fungi, such as those that cause common yeast infections.


Q: What is the typical safety classification of Aureomycin in official documents?

A: The tetracycline drug class, to which Aureomycin belongs, has been assigned a Pregnancy Category D classification by the U.S. FDA. This classification is used to communicate established evidence of risk based on human data.


Q: Do any official warnings exist about driving or operating machinery while taking Aureomycin?

A: Regulatory warnings for the tetracycline class advise that patients should exercise caution when driving vehicles or operating hazardous machinery. This recommendation is specific to those who experience central nervous system symptoms such as dizziness or vertigo.


Q: Why is it important to take Aureomycin with a glass of water?

A: Regulatory guidelines for the tetracycline class generally recommend that the medicine be swallowed whole with a substantial amount of liquid. This practice is intended to minimize the risk of developing esophageal irritation (damage to the food pipe), which is a known class-related adverse effect.

How should Aureomycin be stored and disposed of?

Storage and Disposal of Aureomycin (Chlortetracycline)

Official regulatory labeling dictates specific conditions for storing and disposing of Aureomycin products to maintain stability and prevent hazards.

Domain Required Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F) [FDA DailyMed].
Environmental Protection Protect the product from excessive heat and strong sunlight [FDA DailyMed]. Containers should be kept tightly closed and dry.
Stability/Handling Reconstituted solutions must be prepared daily and are not stable in galvanized containers [FDA DailyMed]. Powder forms require handling to avoid dust accumulation [Health Canada SDS].
Child Safety KEEP OUT OF REACH OF CHILDREN is a mandatory labeling statement [FDA DailyMed].
Disposal Unused medicine must not be thrown into household trash or wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations [Health Canada SDS].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aureomycin found in:

A-Z Index: